Background
==========

Pancreatic cancer (PAC) is an aggressive cancer and its incidence rate has alarmingly increased worldwide. Moreover, PAC is one of the most lethal cancers, with a 5-year survival rate of less than 9% \[[@b1-medscimonit-26-e921769]\]. PAC was the 7^th^ leading cause of cancer death in both males and females worldwide in 2018 \[[@b2-medscimonit-26-e921769]\]. Despite intensive efforts, the prognosis of PAC remains poor mainly due to the absence of early detection biomarkers and limited effective therapeutic strategies \[[@b1-medscimonit-26-e921769],[@b2-medscimonit-26-e921769]\]. Therefore, there is an urgent need to develop accurate diagnostic and prognostic biomarkers so that the optimal treatments can be selected for patients with PAC and thus offer the best hope for cure or extension of lifespan.

Since clinical and pathological characteristics have limited value in early detection and predicting prognosis for PAC, great effort has been made to explore gene biomarkers for PAC. In recent years, accumulated microarray analysis of PAC have been used to identify differentially expressed genes (DEGs) between PAC and non-tumor controls \[[@b3-medscimonit-26-e921769]--[@b8-medscimonit-26-e921769]\]; these studies have made a contribution to discovering the underlying mechanism of PAC and developing biomarkers. Integrated analysis of multiple microarray analysis can help obtain a more accurate profiles of DEGs by using increased sample sizes and avoiding biases induced by different platforms.

Hence, this present study performed an integrated analysis of multiple PAC microarray analyses derived from the GEO to identify accurate DEGs between PAC tissues and non-tumor control tissues. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, and protein--protein integration (PPI) network construction were performed to further research the biological functions of DEGs and the underlying mechanism of PAC. Moreover, the diagnostic and prognostic value of DEGs for PAC was evaluated, which contributes to developing potential biomarkers for PAC.

Material and Methods
====================

Microarray expression profiling of PAC
--------------------------------------

The Gene Expression Omnibus (GEO) is the largest database of high-throughput gene expression data; it is developed and maintained by the National Center for Biotechnology Information. In this present study, datasets of PAC were searched and downloaded from the GEO (*<http://www.ncbi.nlm.nih.gov/geo>*). The inclusion criteria for this study were as follows. First, microarray datasets were expression profiled by array. Second, samples used for microarray datasets were PAC tissues and non-tumor control tissues which included adjacent non-tumor tissues and normal pancreatic tissues.

Identification of DEGs between PAC and non-tumor controls
---------------------------------------------------------

Background correction and normalization were conducted to minimize the heterogeneity among different datasets enrolled in this integrated analysis. By using metaMA in R \[[@b9-medscimonit-26-e921769]\], we calculated effect sizes from unpaired data either from classical or moderated *t*-tests (Limma, SMVar) for each study and combined these effect sizes. *P*-values were corrected separately for multiple test using the false discovery method proposed by Benjamini and Hochberg and the false discovery rate (FDR) was obtained. DEGs between PAC and non-tumor controls were identified with FDR \<0.05 and \|diff\| \>0.5. Hierarchical clustering analysis of DEGs was conducted by using R package "pheatmap" (scale="row", clustering_method="complete" and clustering_distance_rows=" euclidean").

Functional annotation of DEGs
-----------------------------

We used the online-based software GeneCoDis3 (*<http://genecodis.cnb.csic.es/analysis>*), GO, and KEGG molecular pathway enrichment analysis for DEGs between PAC and non-tumor controls. *P*-values were adjusted for multiple test using the Benjamini-Hochberg method and the FDR was obtained. Statistical significance was defined as FDR \<0.05.

Protein--protein interaction (PPI) network
------------------------------------------

To determine the PAC-associated pathways and explore functions of proteins at the molecular level, the top 100 upregulated and downregulated DEGs between PAC and non-tumor controls were applied to construct the PPI network based on the STRING database (*<http://string-db.org>*) and Cytoscape 3.3.0. Proteins with a degree of ≥20 were defined as hub proteins of the PPI network.

Receiver-operating characteristic (ROC) analysis
------------------------------------------------

To access the diagnostic value of DEGs for PAC, receiver-operating characteristic (ROC) of DEGs and the area under the ROC curve (AUC) were calculated by using the "pROC" package. DEGs with AUC \>0.85 were considered to have great diagnostic value for PAC with excellent specificity and sensitivity.

Cross-validation of DEGs
------------------------

The Cancer Genome Atlas (TCGA) project (*<https://tcga-data.nci.nih.gov/tcga/>*) is a public-funded project sponsored by the National Cancer Institute and the National Human Genome Research Institute which stores genomic datasets covering various cancers. The Genotype-Tissue Expression (GTEx) project is a resource database and associated tissue bank for exploring the relationship between genetic variation and gene expression in human tissues \[[@b10-medscimonit-26-e921769]\]. Using R package TCGAbiolinks, the clinical data and gene expression data of 176 pancreatic adenocarcinoma and 167 normal control tissues were downloaded from TCGA and GTEx, respectively. Then, this TCGA-GTEx processed data was used to validate the expression of DEGs identified by this integrated analysis.

Survival analysis
-----------------

The prognostic value of DEGs for PAC patients was further analyzed based on these 176 patients with pancreatic adenocarcinoma in TCGA by using multivariate Cox regression analyses (adjusted for age, sex, grade and stage).

Results
=======

Identification of DEGs between PAC and non-tumor controls
---------------------------------------------------------

A total of 17 GEO microarray datasets \[[@b3-medscimonit-26-e921769]--[@b8-medscimonit-26-e921769],[@b11-medscimonit-26-e921769]--[@b20-medscimonit-26-e921769]\] including 512 PAC tissues and 206 non-tumor control tissues were enrolled in this present study ([Table 1](#t1-medscimonit-26-e921769){ref-type="table"}). Compared with non-tumor controls, 1136 DEGs including 596 upregulated DEGs and 540 downregulated DEGs were identified in PAC. Hierarchical cluster result of DEGs between PAC and non-tumor controls was displayed in [Figure 1](#f1-medscimonit-26-e921769){ref-type="fig"}. [Table 2](#t2-medscimonit-26-e921769){ref-type="table"} showed the top 20 upregulated and downregulated DEGs between PAC and non-tumor controls (sorted by FDR).

Functional annotation
---------------------

Cell proliferation (GO: 0008283, FDR=1.60E-12), Apoptotic process (GO: 0006915, FDR=9.49E-11), Cytoplasm (GO: 0005737, FDR=1.14E-62), Protein binding (GO: 0005515, FDR=1.16E-59), and Microtubule motor activity (GO: 0003777, FDR=7.65E-06) were significantly enriched GO terms for DEGs between PAC and non-tumor controls. The top 20 most significantly enriched GO terms including "biological process", "molecular function", and "cellular component" were displayed in [Figure 2A--2C](#f2-medscimonit-26-e921769){ref-type="fig"}.

After KEGG enrichment analysis, pancreatic secretion (Kegg: 04972, FDR=7.12E-12), pathways in cancer (Kegg: 05200, FDR=1.63E-07), p53 signaling pathway (Kegg: 04115, FDR=1.19E-06), MAPK signaling pathway (Kegg: 04010, FDR=5.13E-06), Insulin signaling pathway (Kegg: 04910, FDR=0.0076) and pancreatic cancer (Kegg: 05212, FDR=0.0264) were significantly enriched pathways for DEGs between PAC and non-tumor controls ([Figure 2D](#f2-medscimonit-26-e921769){ref-type="fig"}). Three upregulated DEGs (RALGDS, E2F3, and RAC1) and 4 downregulated DEGs (EGF, SMAD4, MAPK9, and AKT1) were enriched in pancreatic cancer (Kegg: 05212, [Figure 2E](#f2-medscimonit-26-e921769){ref-type="fig"}).

PPI network
-----------

The PPI network of top 100 upregulated and downregulated DEGs consisted of 174 nodes and 612 edges ([Figure 3](#f3-medscimonit-26-e921769){ref-type="fig"}). Two hub proteins, ALB (degree=34) and BGF (degree=33), were identified based on this PPI network.

ROC analysis
------------

Based on the ROC analysis, a total of 11 DEGs (AHNAK2, CDH3, IFI27, ITGA2, LAMB3, SFN, SLC6A14, TMPRSS4, LAMC2, CEACAM6, and S100P) had great diagnostic value for PAC with AUC more than 0.85 ([Figure 4](#f4-medscimonit-26-e921769){ref-type="fig"}).

Cross-validation
----------------

By using TCGA-GTEx processed data, expression of these 11 DEGs with AUC \>0.85 were validated. All these DEGs were significantly upregulated in pancreatic adenocarcinoma compared with normal controls which was generally consistent with our integrated analysis ([Figure 5](#f5-medscimonit-26-e921769){ref-type="fig"}).

Survival analysis
-----------------

Multivariate Cox regression analyses (adjusted for age, sex, grade, and stage) were performed to evaluate the impact of these 11 above-mentioned DEGs on overall survival of PAC patients. A total of 7 DEGs (AHNAK2, CDH3, IFI27, ITGA2, LAMB3, SLC6A14, and TMPRSS4) with great prognostic value for PAC were identified ([Figure 6](#f6-medscimonit-26-e921769){ref-type="fig"}). Increased expression of these 7 DEGs were significantly associated with poor prognosis of patients with pancreatic adenocarcinoma. Furthermore, these 7 DEGs were dual-functional biomarkers which have both great diagnostic and prognostic value for PAC.

Discussion
==========

Low detection rate in the early stage, and systemic dissemination and insufficient effective treatment contribute to the invariably poor prognosis of patients with PAC. Therefore, development of diagnostic and prognostic biomarkers and therapeutic targets are essential to improve diagnosis accuracy and outcome of PAC patients in the clinic.

After integrated 17 microarray analysis of PAC, a total of 1136 DEGs including 596 upregulated DEGs and 540 downregulated DEGs between PAC and non-tumor controls were identified. Expression of DEGs were confirmed by the TCGA and GTEx. DEGs were significantly enriched in pancreatic secretion (Kegg: 04972), insulin signaling pathway (Kegg: 04910) and several cancer-related pathways including pathways in cancer (Kegg: 05200), MAPK signaling pathway (Kegg: 04010), and pancreatic cancer (Kegg: 05212), which increased the credibility of our integrated analysis.

Eleven upregulated DEGs including (AHNAK2, CDH3, IFI27, ITGA2, LAMB3, SFN, SLC6A14, TMPRSS4, CEACAM6, LAMC2, and S100P) were found to have great ability in discriminating PAC from non-tumor control tissues. These results have been validated by the TCGA-GTEx processed data. Literature-based validation also provided support for our study. Increased expression of 10 DEGs (AHNAK2, CDH3, IFI27, ITGA2, LAMB3, SLC6A14, TMPRSS4, CEACAM6, LAMC2, and S100P) in PAC tissues was confirmed by another microarray analysis in PAC \[[@b21-medscimonit-26-e921769]\]. Lu et al. \[[@b22-medscimonit-26-e921769]\] reported that AHNAK2 is highly expressed in PAC compared to normal tissues by immunohistochemistry. Long et al. \[[@b23-medscimonit-26-e921769]\] found that increased LACM2, ITGA2, and CDH3 were upregulated in PAC at mRNA and protein level using an integrative analysis utilizing next-generation sequencing, transcriptome meta-analysis and immunohistochemistry. Zhang et al. \[[@b24-medscimonit-26-e921769]\] found the upregulation of LAMB3 in pancreatic ductal adenocarcinoma tissues and 7 pancreatic ductal adenocarcinoma cell lines. SLC6A14 was found to be upregulated in pancreatic cancer tissues, cancer cell lines at both mRNA and protein levels \[[@b25-medscimonit-26-e921769]\]. Furthermore, 7 of these 11 DEGs (AHNAK2, CDH3, IFI27, ITGA2, LAMB3, SLC6A14, and TMPRSS4) were found to have great diagnosis and prognostic value for patients with PAC.

Among them, AHNAK2 is a large protein (\>600 kDa) with a PDZ domain that belongs to AHNAK protein family \[[@b26-medscimonit-26-e921769],[@b27-medscimonit-26-e921769]\]. AHNAK2 is a known prognostic biomarker for PAC and increased AHNAK2 was closely associated with the poor prognosis of pancreatic ductal adenocarcinoma (PDAC) \[[@b22-medscimonit-26-e921769]\] which supports this present study.

ITGA2, CDH3, SLC6A14, LAMB3, and TMPRSS4 were all PAC-regulators. Integrin, alpha 2 (ITGA2) was reported to play migrating roles various cancers including pancreas, nasopharyngeal carcinoma \[[@b28-medscimonit-26-e921769]\], colon cancer and gastric cancer.

Cadherin-3 (CDH3) is a novel and useful tumor-associated antigen for immunotherapy against a broad spectrum of cancers such as pancreatic, gastric, and colorectal cancers \[[@b29-medscimonit-26-e921769]\]. SLC6A14 is a neutral and basic amino acid transporter that upregulated in both primary PAC tissues and pancreatic cancer cells lines \[[@b25-medscimonit-26-e921769],[@b30-medscimonit-26-e921769]\] and inhibition of SLC6A14 could decrease pancreatic cell growth and proliferation due to amino acid starvation \[[@b25-medscimonit-26-e921769]\]. LAMB3 involve in the invasion and metastases of multiple cancers such as head and neck squamous cell carcinoma \[[@b31-medscimonit-26-e921769]\], thyroid \[[@b32-medscimonit-26-e921769]\], liver \[[@b33-medscimonit-26-e921769]\], and prostate cancer \[[@b34-medscimonit-26-e921769]\]. Expression of LAMB3 was progressively elevated from tumor initiation to progression \[[@b35-medscimonit-26-e921769]\]. Moreover, LAMB3 play roles in apoptotic, proliferative, invasive, and metastatic in pancreatic cancer via regulating the PI3K/Akt signaling pathway \[[@b24-medscimonit-26-e921769]\]. TMPRSS4 is novel type II transmembrane serine protease that overexpressed in some types of cancers including pancreatic, thyroid, colon, breast, cervical, gastric, and non-small-cell lung cancer \[[@b36-medscimonit-26-e921769]--[@b42-medscimonit-26-e921769]\]. As an important tumor regulator, TMPRSS4 play roles in tumor cell invasion, migration, and metastasis by mediating multiple downstream signaling pathways including focal adhesion kinase (FAK)/MAPK, extracellular signal-regulated kinase (ERK), Akt, Src, Rac1, and JNK signaling pathway \[[@b38-medscimonit-26-e921769],[@b42-medscimonit-26-e921769]--[@b44-medscimonit-26-e921769]\]. Knockdown of TMPRSS4 was found to decrease PDAC cell migration, invasion, and anchorage-independent growth \[[@b27-medscimonit-26-e921769]\]. This present study provided support for these previous studies and emphasized the importance of ITGA2, CDH3, SLC6A14, LAMB3, and TMPRSS in PAC. Moreover, we indicated that these 5 genes could accurately discriminated PAC from non-tumor controls and revealed the association between upregulation of these 5 genes and poor prognosis of patients with PAC.

Notably, the association between IFI27 and PAC has never been reported. IFI27 (interferon alpha inducible protein 27) is an interferon-α (IFN-α) inducible gene that was reported to involve in innate immunity and intervene in cell proliferation. Increased expression of IFI27 has been detected in various other cancers with underlying mechanism not fully understood \[[@b45-medscimonit-26-e921769]\]. IFI27 knockdown induced cholangiocarcinoma cell proliferative rate decreased *in vitro* and *in vivo* and attenuated cholangiocarcinoma cell migration and invasion through inhibition of epithelial-mesenchymal transition \[[@b46-medscimonit-26-e921769]\]. The same phenomenon was observed in oral squamous cell carcinoma as well \[[@b47-medscimonit-26-e921769]\]. In this study, increased expression of IFI27 was found to serve as a poor prognostic biomarker in PAC which providing clues that IFI27 may elicit similar features in PAC.

However, this study had 2 limitations. First, due to restrictions of GEO, the clinical data of datasets used in this study was not detailed enough. This study compared expression profile between PAC tissues and non-tumor controls without classification of normal controls and adjacent non-tumor tissues in PAC patients. Second, wet-lab evidence and larger clinical data sets are needed to confirm our results.

Conclusions
===========

Taken together, our integrated analysis identified 7 dual-function cancer biomarkers (AHNAK2, CDH3, IFI27, ITGA2, LAMB3, SLC6A14, and TMPRSS4) that have both great diagnostic and prognostic value for PAC and it provided clues for the underlying mechanism and therapeutic targets for PAC. Further research is needed to explore their biological function in PAC.
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![Hierarchical clustering analysis of DEGs between PAC and non-tumor controls. Row and column represented DEGs and tissue samples, respectively. The color scale indicated the expression of DEGs while red and green color represented upregulation and downregulation, respectively. DEGs -- differentially expressed genes; PAC -- pancreatic cancer.](medscimonit-26-e921769-g001){#f1-medscimonit-26-e921769}

![Significantly enriched GO terms and KEGG pathways in PAC. (**A--D**) The top 20 significantly biological process, molecular function, cellular component and KEGG pathways enriched for DEGs in PAC are displayed. The y-axis shows GO terms or KEGG pathways and the x-axis represents -logFDR. (**E**) Shows pancreatic cancer (Kegg: 05212). Pink and green rectangles represented the particles that regulated by the upregulated and downregulated DEGs between PAC and non-tumor controls, respectively. DEGs -- differentially expressed genes; PAC -- pancreatic cancer; GO -- Gene Ontology; KEGG -- Kyoto Encyclopedia of Genes and Genomes.](medscimonit-26-e921769-g002){#f2-medscimonit-26-e921769}

![PPI network. Rosy and green rectangles represent proteins encoded by upregulated and downregulated DEGs, respectively. Edges indicate integrations between proteins. PPI -- protein--protein integration; DEGs -- differentially expressed genes.](medscimonit-26-e921769-g003){#f3-medscimonit-26-e921769}

![ROC curves of DEGs with great diagnostic value for PAC. Gene symbols was on the top of the ROC curves. The x-axis shows 1-specificity and y-axis shows sensitivity, respectively. ROC -- receiver-operating characteristic; DEGs -- differentially expressed genes.](medscimonit-26-e921769-g004){#f4-medscimonit-26-e921769}

![Cross-validation of DEGs by TCGA and GTEx Box-plot displayed the expression levels of DEGs between PAAD and non-tumor tissues. (**A**) AHNAK2; (**B**) CDH3; (**C**) IFI27; (**D**) ITGA2; (**E**) LAMB3; (**F**) SFN; (**G**) SLC6A14; (**H**) TMPRSS4; (**I**) CEACAM6; (**J**) LAMC2; (**K**) S100P. The x-axis represents PAAD and normal groups. The y-axis represents relative gene expression levels. DEGs -- differentially expressed genes; TCGA -- The Cancer Genome Atlas; GTEx -- Genotype-Tissue Expression; PAAD -- pancreatic adenocarcinoma.](medscimonit-26-e921769-g005){#f5-medscimonit-26-e921769}

![Survival analysis of DEGs with great prognostic value for PAC. (**A**) AHNAK2; (**B**) CDH3; (**C**) IFI27; (**D**) ITGA2; (**E**) LAMB3; (**F**) SLC6A14; (**G**) TMPRSS4. The x-axis indicates times (days) and y-axis indicates survival rate. High expression of these eight DEGs was significantly associated with lower survival rate in patients with PAC. DEGs -- differentially expressed genes; PAC -- pancreatic cancer.](medscimonit-26-e921769-g006){#f6-medscimonit-26-e921769}

###### 

Gene expression datasets used in this study.

  GEO accession   Control   Case   Platform                                                                                    Year   Country          Author
  --------------- --------- ------ ------------------------------------------------------------------------------------------- ------ ---------------- -------------------------------------------------
  GSE107610       2         39     GPL15207\[PrimeView\] Affymetrix Human Gene Expression Array                                2018   Japan            Shimokawa M. \[[@b4-medscimonit-26-e921769]\]
  GSE101448       19        24     GPL10558Illumina HumanHT-12 V4.0 expression beadchip                                        2018   Germany          Busch H. \[[@b5-medscimonit-26-e921769]\]
  GSE46234        4         4      GPL570\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array                        2017   Norway           Ræder H. \[[@b12-medscimonit-26-e921769]\]
  GSE63111        7         28     GPL5188\[HuEx-1_0-st\] Affymetrix Human Exon 1.0 ST Array \[probe set (exon) version\]      2017   United Kingdom   Wang J. \[[@b6-medscimonit-26-e921769]\]
  GSE62165        13        118    GPL13667\[HG-U219\] Affymetrix Human Genome U219 Array                                      2016   Belgium          Janky R. \[[@b7-medscimonit-26-e921769]\]
  GSE62452        61        69     GPL6244\[HuGene-1_0-st\] Affymetrix Human Gene 1.0 ST Array \[transcript (gene) version\]   2016   USA              Hussain P.S. \[[@b8-medscimonit-26-e921769]\]
  GSE71989        8         13     GPL570\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array                        2015   USA              Schmittgen T. \[[@b13-medscimonit-26-e921769]\]
  GSE27890        4         4      GPL570\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array                        2014   USA              Bowen N.J. \[[@b14-medscimonit-26-e921769]\]
  GSE56560        7         28     GPL5175\[HuEx-1_0-st\] Affymetrix Human Exon 1.0 ST Array \[transcript (gene) version\]     2014   United Kingdom   Wang J. \[[@b9-medscimonit-26-e921769]\]
  GSE58561        2         3      GPL14550Agilent-028004 SurePrint G3 Human GE 8x60K Microarray (Probe Name Version)          2014   Norway           Sandhu V. \[[@b15-medscimonit-26-e921769]\]
  GSE55643        8         45     GPL6480Agilent-014850 Whole Human Genome Microarray 4x44K G4112F (Probe Name version)       2014   United Kingdom   Jamieson N.B. \[[@b16-medscimonit-26-e921769]\]
  GSE23397        6         15     GPL5188\[HuEx-1_0-st\] Affymetrix Human Exon 1.0 ST Array \[probe set (exon) version\]      2013   Germany          Holzmann K.
  GSE41368        6         6      GPL6244\[HuGene-1_0-st\] Affymetrix Human Gene 1.0 ST Array \[transcript (gene) version\]   2013   Italy            Colombo T. \[[@b17-medscimonit-26-e921769]\]
  GSE43795        5         7      GPL10558Illumina HumanHT-12 V4.0 expression beadchip                                        2013   South Korea      Park N. \[[@b18-medscimonit-26-e921769]\]
  GSE28735        45        45     GPL6244\[HuGene-1_0-st\] Affymetrix Human Gene 1.0 ST Array \[transcript (gene) version\]   2012   USA              Hussain P. \[[@b19-medscimonit-26-e921769]\]
  GSE32676        7         25     GPL570\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array                        2011   USA              Tran L.M. \[[@b20-medscimonit-26-e921769]\]
  GSE15471        39        39     GPL570\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array                        2009   Romania          Badea L. \[[@b21-medscimonit-26-e921769]\]

###### 

Top 20 up- and down-regulated DEGs between pancreatic cancer and non-tumor controls.

  Gene ID   Gene symbol   Diff       Regulation   Gene id   Gene symbol   Diff       Regulation
  --------- ------------- ---------- ------------ --------- ------------- ---------- ------------
  6286      S100P         1.851675   Up           5407      PNLIPRP1      −2.52947   Down
  4680      CEACAM6       1.809022   Up           1358      CPA2          −2.44332   Down
  1048      CEACAM5       1.74063    Up           1208      CLPS          −2.30786   Down
  3918      LAMC2         1.619369   Up           5408      PNLIPRP2      −2.29361   Down
  10103     TSPAN1        1.592894   Up           5319      PLA2G1B       −2.27519   Down
  11254     SLC6A14       1.51112    Up           5406      PNLIP         −2.26446   Down
  11199     ANXA10        1.504241   Up           1357      CPA1          −2.24956   Down
  6364      CCL20         1.491776   Up           11330     CTRC          −2.10615   Down
  3429      IFI27         1.47296    Up           2813      GP2           −2.10261   Down
  56649     TMPRSS4       1.455704   Up           440387    CTRB2         −2.10088   Down
  3880      KRT19         1.44997    Up           1360      CPB1          −2.09227   Down
  1728      NQO1          1.398528   Up           5968      REG1B         −2.01307   Down
  10874     NMU           1.39464    Up           50624     CUZD1         −1.98905   Down
  22943     DKK1          1.347667   Up           1506      CTRL          −1.98238   Down
  51208     CLDN18        1.343661   Up           121506    ERP27         −1.87554   Down
  195814    SDR16C5       1.342804   Up           5276      SERPINI2      −1.80644   Down
  2877      GPX2          1.326222   Up           213       ALB           −1.73523   Down
  7031      TFF1          1.298329   Up           8671      SLC4A4        −1.73172   Down
  4312      MMP1          1.296652   Up           2494      NR5A2         −1.64221   Down
  29089     UBE2T         1.289073   Up           5166      PDK4          −1.62103   Down

Diff -- mean expression of pancreatic cancer minus mean expression of non-tumor controls.
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